Sadhana Jackson, M.D.
Dr. Jackson’s research interests center on evaluating the blood-brain barrier (BBB) of malignant gliomas. Her clinical and translational research focuses on transiently disrupting the BBB by pharmacologic means, in an effort to improve cytotoxic therapy to the central nervous system. She uses brain microdialysis, pharmacokinetic analysis, and preclinical models to study central nervous system (CNS) pharmacology. Dr. Jackson also leads collaborative preclinical and clinical studies focused on understanding BBB integrity in normal brain and malignant gliomas with the goal of developing novel treatment strategies for brain tumor patients.
Dr. Jackson is an Adjunct Investigator in CCR's Pediatric Oncology Branch.
1) neuro-oncology, 2) blood-brain barrier, 3) drug delivery, 4) pharmacokinetics, 5) malignant brain tumors
Center for Cancer Research
National Cancer Institute
Building 10, Room 7D45
Bethesda, MD 20892
One of the major obstacles to effectively treating central nervous system (CNS) tumors is the integrity of the blood-brain barrier (BBB). The BBB prevents systemic drug delivery from reaching the brain and brain tumor tissue. While previous studies have mainly focused on circumventing the BBB, very few agents or mechanisms have been explored that modulate the tumor microenvironment to enhance effective therapies for malignant brain tumors.
Dr. Jackson's studies focus on understanding the heterogeneity of BBB permeability amongst malignant tumor cells and the role of the supportive BBB in tumor growth. Her collaborative laboratory and clinical investigations center around BBB biology, cancer biology, pharmacokinetics and pharmacodynamics related to optimal CNS drug delivery.
Selected Recent Publications
- Biomaterials. 214: 119217, 2019. [ Journal Article ]
The effect of an adenosine A(2A) agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.Fluids Barriers CNS. 15(1): 2, 2018. [ Journal Article ]
- J Neurooncol. 132(3): 513-519, 2017. [ Journal Article ]
- Front Cell Neurosci. 11: 318, 2017. [ Journal Article ]
The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.J Neurooncol. 126(3): 433-9, 2016. [ Journal Article ]
Dr. Jackson attended Hampton University where she received her Bachelor of Science in Molecular Biology. She then obtained her M.D. from Eastern Virginia Medical School (EVMS). Dr. Jackson subsequently completed a residency in Pediatrics at Orlando Health and afterwards completed her pediatric hematology/oncology fellowship at St. Jude Children’s Research Hospital. Additionally, she completed a joint pediatric neuro-oncology and clinical pharmacology fellowship at Johns Hopkins Medical Institute before being selected as an NCI Assistant Clinical Investigator in the Clinical Investigator Development Program in 2015.
Dr. Sadhana Jackson is a board-certified pediatrician and pediatric hematologist/oncologist with clinical expertise and research efforts related to the blood-brain barrier and malignant gliomas. Dr. Jackson’s clinical practice focuses on drug delivery of systemic agents for pediatric malignant brain tumor patients. She has extensive experience with use of intracerebral microdialysis and intratumoral/peritumoral pharmacology to evaluate optimal drug entry in malignant brain tumors.